Avenge Bio’s AVB-001 Granted FDA Orphan Drug Designation for Mesothelioma Treatment
Avenge Bio, Inc., a leading biotech firm specializing in oncology, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AVB-001. This designation recognizes AVB-00 ...
Verismo Therapeutics Receives Fast Track Designation from FDA for SynKIR-110, a Novel CAR T Therapy for Mesothelioma Treatment
Verismo Therapeutics, a clinical-stage company specializing in CAR T technology, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its innovative drug, SynKIR-11 ...